Zymenex moves rare disease treatment into Phase II trials
This article was originally published in Scrip
Executive Summary
Zymenex' rare disease treatment Lamazym (recombinant human lysosomal enzyme alpha-mannosidase, rhLAMAN) has entered into Phase IIa testing for the treatment of alpha-mannosidosis following positive results in early clinical testing.